24/7 Crypto Derivatives Access Might Change The Case For Investing In CME Group (CME)

• CME Group announced that, pending regulatory approval, its cryptocurrency futures and options will become available for 24/7 trading on CME Globex in early 2026, marking a major expansion in access to regulated crypto derivatives markets.
• This move aims to address strong institutional demand for continuous risk management, aligning CME Group with decentralized finance standards and reflecting record-breaking volumes in its crypto products throughout 2025.
• We'll explore how CME Group's planned introduction of 24/7 crypto derivatives trading could influence its long-term growth narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

CME Group Investment Narrative Recap

To be a CME Group shareholder, you need to believe in the enduring importance of centralized market infrastructure, especially as demand for risk management stays strong amid global uncertainty. The company's expansion to 24/7 crypto derivatives trading speaks directly to ongoing catalysts like product innovation and international broadening but doesn't materially change the short-term driver: whether elevated volatility sustains strong trading volumes. The biggest risk remains rapid adoption of decentralized platforms, which could shift activity away from centralized venues like CME.

Among recent company news, the upcoming launch of Solana and XRP options stands out for directly complementing CME’s crypto expansion. By adding these products, CME strengthens the breadth and depth of its crypto offerings, stacking the odds in favor of staying relevant as institutional and retail adoption of digital assets continues to fuel volume growth.

Yet, in contrast, investors should be aware that decentralized finance adoption poses long-term risks to CME’s market share…

Read the full narrative on CME Group (it's free!)

CME Group's outlook anticipates $7.3 billion in revenue and $4.3 billion in earnings by 2028. This scenario assumes a 4.4% annual revenue growth rate and a $0.6 billion increase in earnings from the current $3.7 billion.

Uncover how CME Group's forecasts yield a $282.11 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Five individual fair value estimates from the Simply Wall St Community span US$175.71 to US$282.11 per share. While some see new product innovation driving future gains, others caution that technology shifts could affect CME Group’s competitive edge, explore these viewpoints to see where you stand.

Explore 5 other fair value estimates on CME Group - why the stock might be worth as much as 7% more than the current price!

Build Your Own CME Group Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CME Group research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CME Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CME Group's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are the new gold rush. Find out which 35 stocks are leading the charge.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com